Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Current Liabilities (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Total Current Liabilities data on record, last reported at $16.4 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 43.34% year-over-year to $16.4 million; the TTM value through Dec 2025 reached $16.4 million, down 43.34%, while the annual FY2025 figure was $16.4 million, 43.34% down from the prior year.
  • Total Current Liabilities reached $16.4 million in Q4 2025 per VRCA's latest filing, down from $28.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $46.4 million in Q3 2021 and bottomed at $2.6 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $25.5 million, with a median of $25.0 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: plummeted 94.1% in 2023, then surged 632.69% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $46.1 million in 2021, then tumbled by 92.49% to $3.5 million in 2022, then skyrocketed by 392.17% to $17.0 million in 2023, then skyrocketed by 70.42% to $29.0 million in 2024, then tumbled by 43.34% to $16.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $16.4 million in Q4 2025, $28.9 million in Q3 2025, and $29.2 million in Q2 2025.